Background-Our objective was to determine whether abciximab, eptifibatide, or tirofiban inhibited ligand binding to ␣ v ␤ 3 integrins on human aortic smooth muscle cells (HASMCs) or human umbilical vein endothelial cells (HUVECs). Abciximab binds ␣ IIb ␤ 3 on platelets and ␣ v ␤ 3 on HUVECs with similar affinity, whereas eptifibatide and tirofiban are thought to be highly specific for ␣ IIb ␤ 3 . The conclusion that eptifibatide does not bind vascular ␣ v ␤ 3 integrins may be premature, however, because recent studies have demonstrated that the affinity of ␣ v ␤ 3 for various ligands, including antagonists, is subject to modulation. Methods and Results-Abciximab and 7E3, the anti-␤ 3 integrin monoclonal antibody from which abciximab was derived, bound ␣ v ␤ 3 on HASMCs in a specific and saturable manner and with an affinity similar to binding to ␣ IIb ␤ 3 on platelets. 7E3 and eptifibatide inhibited ␣ v ␤ 3 -mediated attachment of HASMCs to thrombospondin (TSP) and prothrombin but had no effect on ␣ v ␤ 5 -or ␤ 1 -mediated HASMC attachment to vitronectin-, collagen-, or fibronectin-coated or noncoated tissue culture plates. The inhibitory effect of eptifibatide was similar in magnitude and not additive to that of 7E3. Eptifibatide and 7E3 inhibited ␣ v ␤ 3 -mediated attachment of HUVECs. Tirofiban had only nonspecific effects on HASMC attachment to extracellular matrix proteins. In cell proliferation assays, eptifibatide inhibited ␣ v ␤ 3 -mediated responses to soluble TSP by HASMCs and ␤ 3 integrin-expressing HEK cells. Conclusions-Eptifibatide and 7E3, but not tirofiban, specifically inhibit ␣ v ␤ 3 -mediated binding of human smooth muscle and endothelial cells. (Circulation. 2001;104:582-587.) 
T he ␤ 3 integrins play an important role in vascular disease. ␣ IIb ␤ 3 integrins are critically important in platelet aggregation and thrombus formation, whereas ␣ v ␤ 3 integrins have been implicated in mediating vascular repair. Vascular injury is a potent stimulus for expression of ␤ 3 integrins, 1,2 and treatment with ␣ v ␤ 3 antagonists reduces (neo)intima formation after injury of rat carotid, 3 rabbit carotid, 4 hamster carotid, 5 pig coronary, 2 pig carotid and femoral, 6 and rabbit iliac 7, 8 arteries.
The central role of ␣ IIb ␤ 3 in thrombosis led to the development of pharmaceutical agents that block interactions between ␣ IIb ␤ 3 and fibrinogen. All 3 currently available agents (tirofiban, abciximab, and eptifibatide) exhibit high-affinity binding to ␣ IIb ␤ 3 , inhibit ex vivo platelet aggregation, and reduce clinical thrombotic events. 9 Abciximab is an antigenbinding fragment (c7E3) derived from monoclonal anti-␤ 3 integrin antibody 7E3 that binds ␣ IIb ␤ 3 and ␣ v ␤ 3 with equal affinity. 10 In contrast, both eptifibatide and tirofiban are small-molecule inhibitors that are thought to be highly specific for ␣ IIb ␤ 3 . The conclusion that eptifibatide does not interact with ␣ v ␤ 3 is based on studies showing that eptifi-batide did not inhibit vitronectin binding to purified ␣ v ␤ 3 at concentrations 50-fold higher than the IC 50 for inhibition of fibrinogen binding to ␣ IIb ␤ 3 . 11 Recent work has shown that ␣ v ␤ 3 binding is a dynamic process with (1) activationdependent and activation-independent ligands, (2) variable basal affinity state of ␣ v ␤ 3 among different cell types, and (3) acute modulation of the affinity of ␣ v ␤ 3 for ligands by "inside-out" signals. [12] [13] [14] Thus, the finding that eptifibatide did not inhibit binding of vitronectin to purified ␣ v ␤ 3 in a cell-free system does not necessarily exclude all interactions between eptifibatide and ␣ v ␤ 3 on the surface of vascular cells.
Acute vascular injury leads to the concentration of numerous extracellular matrix proteins in the vessel wall. Among these proteins are thrombospondin 1 (TSP), which binds endothelial cells and smooth muscle cells (SMCs) via ␣ v ␤ 3 integrins. 15 We have been particularly interested in TSP because of recent evidence that (1) treatment with an anti-TSP antibody inhibited SMC proliferation and reduced neointimal formation after carotid injury in the rat, 16 and (2) TSP-induced proliferation of SMCs is mediated by interactions with ␣ v ␤ 3 integrins. 1, 17 Because the efficacy of ␣ v ␤ 3 antagonists varies depending on the cell type and ligand studied, the aim of the present studies was to examine the effects of 7E3, eptifibatide, and tirofiban on vascular cell interactions with TSP.
Methods

Reagents
Vitronectin, collagen, fibronectin, prothrombin, echistatin, and GRGES peptides were obtained from Sigma Chemical Co. TSP was purified from recently outdated human platelets by a modification of the method described by Santoro and Frazier. 1 The level of transforming growth factor-␤ in TSP preparations was Ͻ0.15 ng/mL. Eptifibatide was obtained from Cor Therapeutics and 7E3, c7E3, and 10E5 from Centocor.
Cell Culture, Proliferation Assays, and Flow Cytometric Analysis
Human aortic SMCs (HASMCs) were obtained from Clonetics and maintained in culture as previously described. 1 Ca 2ϩ was present at a concentration of 1.60ϫ10 Ϫ3 mol/L in the medium. Human umbilical vein endothelial cells (HUVECs) were a gift from C. Patterson, MD (University of North Carolina, Chapel Hill) and were cultured by standard techniques. Fluorescence-activated cell sorter analysis was performed as described by Pampori et al. 14 
Cell Adhesion Assay
Twenty-four-well plates were coated and then blocked with 3% BSA. HASMCs or HUVECs in suspension were treated with peptides or antibodies as indicated and then added to plates and incubated for 60 minutes at 37°C. Nonadherent cells were removed by washing, and PBS containing 0.5% crystal violet was added. The cells were then washed 3 times in PBS and visualized by light microscopy. Cell binding was quantified by measurement of optical density. Adhesion in the absence of any inhibitors was assigned the value of 100%.
Receptor Binding Studies
These studies were performed as previously described. 1 Briefly, c7E3 or 7E3 was radiolabeled and diluted in growth-arrest medium containing 0.02% azide to prevent internalization. HASMCs were incubated with antibodies for 4 hours at 37°C, and bound radioactivity was quantified with a gamma counter. For competition binding, the ability of unlabeled antibodies to compete with 0.2 g/mL 125 I-labeled 7E3 binding was determined.
Transfection and Selection of Stable ␤ 3 Integrin-Expressing HEK Cells
pcDNA-1neo constructs encoding full-length ␤ 3 subunits were a gift of D. Cheresh (Scripps Research Institute, La Jolla, Calif) and have been described previously. 18 ␤ 3 integrin-deficient HEK 293 cells (ATCC) were cultured in DMEM supplemented with 10% heat-inactivated horse serum. When the cells were semiconfluent, the medium was changed to DMEM without serum, and transfection was performed with the FuGENE Transfection Reagent (Boehringer Mannheim). Six hours later, the medium was changed to DMEM with 10% serum for 72 hours. G418 (500 g/mL) was then added until stable cell lines were established.
Statistical Analysis
Results are presented as meanϮSEM from Ն3 independent experiments. The data were analyzed by ANOVA followed by the Tukey multiple range test. A value of PՅ0.05 was considered statistically significant.
Results
Abciximab Binds HASMCs in a Specific and Saturable Manner
Saturation binding experiments revealed that the affinity of abciximab (c7E3) for HASMCs (K d ϭ6.9Ϯ2.8 nmol/L; Figure  1A ) was similar to that for HUVECs, platelets, and purified ␣ v ␤ 3 . 10 The affinity of c7E3 for HASMCs was less than that of 7E3 (K d ϭ3.8Ϯ0.4 nmol/L), but at concentrations Ͼ10 g/mL, 7E3 and c7E3 had similar effects in competing for binding to ␣ v ␤ 3 on HASMCs ( Figure 1B) . The binding affinities of c7E3 and 7E3 were both significantly less than that of LM609 (K d ϭ0.18Ϯ0.01 nmol/L; Figure 1A ), a monoclonal antibody that is highly specific for ␣ v ␤ 3 . There were 132 000Ϯ28 000 binding sites for c7E3 and 91 000Ϯ6000 binding sites for 7E3 per HASMC, consistent with the monovalent binding of abciximab and bivalent binding of 7E3 observed previously for platelets and HUVECs. 10 
␤ 3 Subunits Form Heterodimers Primarily, if Not Solely, With ␣ v Subunits in HASMCs
Binding of 7E3 to HASMCs was almost completely inhibited by LM609 ( Figure 1B) . The monoclonal antibody 10E5, which binds ␣ IIb ␤ 3 , had no effect on 7E3 binding. The fluorescence patterns on flow cytometry observed with LM609 and 7E3 were nearly identical ( Figure 1C ). Minimal staining was observed with 10E5 ( Figure 1C ) or with HIP8, a monoclonal IgG1 that reacts with the calcium-dependent complex of ␣ IIb ␤ 3 expressed on human platelets (data not shown). These results demonstrate that ␤ 3 subunits form heterodimers primarily, if not solely, with ␣ v subunits in HASMCs.
Eptifibatide and Tirofiban Inhibited HASMC Adhesion to TSP
Eptifibatide and tirofiban inhibited attachment of HASMCs to TSP-coated plates in a dose-dependent manner ( Figure  2A) . At a concentration of 30 mol/L, eptifibatide inhibited attachment by 37%. Tirofiban was Ϸ1 order of magnitude less potent than eptifibatide in this assay. Echistatin, a disintegrin found in the venom of Echis carinatus that binds ␣ v ␤ 3 on SMCs with high specificity, 19 inhibited HASMC attachment to TSP with a potency Ϸ100-fold and 1000-fold greater than those of eptifibatide and tirofiban, respectively ( Figure 2B ). Treatment with GRGES peptides had no effect on HASMC attachment.
Incubation with 7E3 (30 g/mL) inhibited HASMC attachment to TSP by 31% (PϭNS, eptifibatide 30 mol/L versus 7E3). Higher concentrations of 7E3 had the same inhibitory effect as 30 g/mL (PϭNS, 7E3 30 g/mL versus 7E3 100 g/mL), and thus this concentration was used for the remainder of our studies ( Figure 2C ). Combined treatment with eptifibatide and 7E3 had the same inhibitory effect as eptifibatide or 7E3 alone. Treatment with the monoclonal anti-␣ IIb ␤ 3 antibody 10E5, at a dose 15-fold greater than that necessary to block attachment of genetically manipulated CHO cells expressing ␣ IIb ␤ 3 to fibrinogen, 20 had no effect on HASMC attachment to TSP.
Inhibitory Effects of 7E3 and Eptifibatide, but Not Tirofiban, Were Specific for ␣ v ␤ 3 Integrins
HASMCs attach to various matrix proteins via different integrins, and we examined adhesion to prothrombin-, vitronectin-, collagen-, and fibronectin-coated and noncoated plates to determine the specificity of the inhibitory effects of 7E3, eptifibatide, and tirofiban. Prothrombin and vitronectin support ␣ v ␤ 3 -mediated 13 and ␣ v ␤ 5 -mediated 21,22 attachment of HASMCs, respectively, whereas attachment to collagen-and fibronectin-coated and noncoated plates is mediated by various ␤ 1 integrins. 23 Eptifibatide inhibited HASMC attachment to prothrombin in a dose-dependent manner ( Figure 3A) . At a concentration of 30 mol/L, eptifibatide inhibited HASMC attachment to prothrombin by 38%, an effect similar in magnitude to that observed with 7E3. 10E5 had a small, statistically nonsignificant effect on attachment to prothrombin.
Neither 7E3 nor eptifibatide inhibited HASMC attachment to vitronectin-coated plates ( Figure 3B ). These results are consistent with previous studies of human aortic 21 and human iliac 22 SMCs in which 7E3 at concentrations of 20 and 60 g/mL had no effect on adhesion to vitronectin. Similarly, neither 7E3 nor eptifibatide had any effect on HASMC attachment to collagen-or fibronectin-coated or noncoated tissue culture plates ( Figure 3B ).
Tirofiban at a concentration of 30 mol/L inhibited HASMC attachment to TSP-, prothrombin-, collagen-, vitronectin-, and fibronectin-coated and noncoated plates by 5% to 20% (Figures 2 and 3) . The ability of tirofiban to inhibit attachment of HASMCs to vitronectin-, collagen-, and fibronectin-coated and noncoated plates demonstrates that tirofiban has inhibitory effects independent of ␣ v ␤ 3 integrins.
Eptifibatide Inhibited Proliferative Responses to Soluble TSP
In previous studies, 1 we found that TSP-induced proliferation of HASMCs was mediated by ␣ v ␤ 3 , and we used this assay to determine the functional significance of eptifibatide/␣ v ␤ 3 interactions. For these studies, HASMCs were plated on noncoated tissue culture dishes, grown to subconfluence, and then growtharrested. Soluble TSP (25 g/mL) was added and stimulated a modest proliferative response (125Ϯ6% of vehicle-treated groups). Treatment with eptifibatide inhibited 84Ϯ8% of this response, similar to the effect of 7E3 (71Ϯ9%, PϭNS, eptifibatide versus 7E3; Figure 4 ). Eptifibatide did not inhibit proliferative responses to platelet-derived growth factor BB (PDGF-BB) or 10% serum. Tirofiban and GRGES peptides had no effect on proliferative responses to TSP, PDGF-BB, or serum.
Antiproliferative Effect of Eptifibatide Was Mediated by ␤ 3 Integrins
To determine whether the antiproliferative effect of eptifibatide was due to specific interactions with ␤ 3 integrins, we used human embryonic kidney (HEK) cells that express ␣ v subunits but not ␤ 3 subunits. These cells were transfected with pcDNA-1neo constructs 18 encoding ␤ 3 integrin subunits. Stable expression of ␤ 3 integrins and formation of ␣ v ␤ 3 complexes was confirmed by immunoprecipitation with LM609 followed by Western analysis (Figure 5A ).
HEK cells that expressed ␤ 3 subunits proliferated at a rate that was 65% greater than mock-transfected HEK cells when grown in 10% serum on standard tissue culture plates. After growth arrest, ␤ 3 -transfected, but not mock-transfected, HEK cells proliferated in response to TSP. The proliferative response to TSP in ␤ 3 -transfected HEK cells was 88% inhibited by eptifibatide ( Figure 5B ).
Eptifibatide Inhibited HUVEC Attachment to TSP and Vitronectin
Eptifibatide inhibited the attachment of HUVECs to TSP in a dose-dependent manner ( Figure 6 ). The inhibitory effects of eptifibatide (30 mol/L) and 7E3 were similar in magnitude (54% and 57%, respectively) and not additive. Endothelial cells, in contrast to SMCs, adhere to vitronectin via ␣ v ␤ 3 , 15, 22 and we found that eptifibatide inhibited endothelial cell attachment to vitronectin by 30Ϯ9% (PϽ0.05 compared with control), an effect that was the same in magnitude as that observed with 7E3 (40Ϯ8%; PϽ0.05 compared with control; PϭNS, eptifibatide versus 7E3).
Discussion
Our results demonstrate that eptifibatide can inhibit ligand binding to ␣ v ␤ 3 under specific conditions. This conclusion is based on findings that (1) eptifibatide inhibited HASMC and HUVEC attachment to TSP, events mediated by ␣ v ␤ 3 15 ; (2) the inhibitory effect of eptifibatide was quantitatively similar to and not additive to that observed with 7E3; (3) eptifibatide inhibited HASMC adhesion to prothrombin and HUVEC The inhibitory effects of eptifibatide on HASMC adhesion and proliferation were specific for ␣ v ␤ 3 . High doses of eptifibatide did not interfere with HASMC adhesion to vitronectin, fibronectin, collagen, or standard tissue culture plates, events that are mediated primarily by ␣ v ␤ 5 21 or ␤ 1 integrins. 23 Furthermore, the inhibitory effect of eptifibatide on HASMC attachment to TSP and prothrombin cannot be attributed to eptifibatide binding to ␣ IIb ␤ 3 , for 3 reasons. First, Western analysis and flow cytometry confirmed that HASMCs do not express ␣ IIb subunits. Second, attachment to TSP or prothrombin was not inhibited by high concentrations of a function-blocking anti-␣ IIb ␤ 3 antibody (10E5). And third, the inhibitory effects of eptifibatide were similar to and not additive to those of 7E3. As shown in Figure  1 , binding of 7E3 to human aortic HASMCs is mediated via ␣ v ␤ 3 and not ␣ IIb ␤ 3 .
Antagonism of ␣ v ␤ 3 integrins may have important antithrombotic and anti-inflammatory effects in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. ␣ v ␤ 3 is a receptor for soluble prothrombin, 13 and combined blockade of ␣ v ␤ 3 and ␣ IIb ␤ 3 was significantly more effective at reducing platelet-mediated thrombin generation than blockade of either ␣ v ␤ 3 or ␣ IIb ␤ 3 alone. 24 Furthermore, in a study 25 that used plasma from patients with acute myocardial infarction, the adhesion of platelets to the luminal surface of activated HUVECs was inhibited Ϸ50% by various ␣ v ␤ 3 antagonists. There is also evidence that ␣ v ␤ 3 functions in adherence of leukocytes to endothelial cells and matrix proteins, fibrin clot retraction by nucleated cells, SMC migration and proliferation, vascular cell apoptosis, vascular remodeling, and intimal formation. [2] [3] [4] [5] [6] [7] [8] 26 An important, unresolved question is whether either abciximab or eptifibatide has effects on vascular cells in patients with unstable angina or undergoing percutaneous coronary intervention. The average steady-state plasma concentrations in patients receiving FDA-approved doses were 1.8 to 2.4 mol/L with Figure 5 . Effects of eptifibatide on proliferative responses of HEK cells. ␤ 3 integrin-deficient HEK cells were transfected with an empty vector or pcDNA-1neo constructs encoding full-length ␤ 3 integrin subunits. Immunoprecipitation using LM609 followed by Western analysis with an anti-␤ 3 integrin antibody confirmed expression (A). Cells were grown in serum-containing medium for 5 days and then growth-arrested in 0.5% FBS for 4 days. Soluble TSP (25 g/mL) or vehicle was added Ϯ eptifibatide (30 mol/L) or GRGES (30 mol/L). Cell number assays were performed 72 hours later. All groups were compared with mocktransfected cells that were not exposed to TSP (B). *PϽ0.05 vs control. eptifibatide (A. True, PharmD, Cor Therapeutics, personal communication) and 0.2 to 0.4 g/mL with abciximab. 27 There was wide individual variation, however, in plasma levels. Furthermore, plasma concentrations of abciximab may not reflect concentrations in the injured artery, because the drug is largely platelet-bound, with continuous redistribution among ␣ v ␤ 3 and ␣ IIb ␤ 3 in vitro 10 and also possibly between platelets and ␣ v ␤ 3 in the vessel wall in vivo. Thus, although we found that eptifibatide had effects on cultured vascular cells at concentrations closer to those obtained in plasma during clinical use than did abciximab, an understanding of whether abciximab or eptifibatide interacts with ␣ v ␤ 3 in injured blood vessels must await direct study, including determination of local concentrations of the drugs within the arterial wall and time course of expression and accessibility of ␣ v ␤ 3 receptors.
Our results provide further evidence that ␣ v ␤ 3 integrins exist in multiple conformations and are subject to modulation. Scarborough et al 11 found that eptifibatide did not block vitronectin binding to purified ␣ v ␤ 3 , whereas we found that eptifibatide blocked TSP binding to ␣ v ␤ 3 on HASMCs and HUVECs, and Pampori et al 14 reported that low concentrations of eptifibatide (1 mol/L) partially blocked binding of ␤ 3 integrin ligands to genetically manipulated CHO cells expressing ␣ v ␤ 3 . ␣ v ␤ 3 conformation in cultured cells is regulated by PMA, Mn 2ϩ , and ADP, 13 but factors that control conformational state in vivo are unknown.
We found that abciximab bound to HASMCs with an affinity (K d ϭ6.9Ϯ2.8 nmol/L) similar to that for binding to HUVECs (K d ϭ9.8Ϯ2.7 nmol/L), human coronary SMCs (K d ϭ14Ϯ8.4 nmol/L), purified ␣ v ␤ 3 (K d ϭ11.0Ϯ3.2 nmol/L), and ␣ IIb ␤ 3 (K d ϭ6.2Ϯ2.7 nmol/L) on platelets. 10 The affinity of abciximab for HASMCs was more than an order of magnitude less than that of LM609 (K d ϭ0.18Ϯ0.01 nmol/L), a monoclonal antibody that is highly specific for ␣ v ␤ 3 . c7E3 was slightly less efficient at competing for binding to HASMCs than 7E3, similar to previous results in HUVECs. 10 We found no evidence that tirofiban specifically interacts with ␣ v ␤ 3 , even at concentrations 300-fold greater than those obtained in plasma during clinical usage (Ϸ100 nmol/L 28 ). Tirofiban had the same inhibitory effect on HASMC attachment to vitronectinor collagen-coated or noncoated plates, events not mediated by ␣ v ␤ 3 , as it did on HASMC attachment to TSP or prothrombin. Moreover, tirofiban did not inhibit TSP-induced proliferation and had no effect on HUVEC attachment to TSP, events that are mediated by ␣ v ␤ 3 . Our results are consistent with those of previous studies that found that tirofiban at a concentration of 120 mol/L did not block HUVEC attachment to or spreading on vitronectin. 22 The different affinities of eptifibatide and tirofiban for ␣ v ␤ 3 are not surprising, given that eptifibatide is a synthetic, cyclic peptide with a Lys-Gly-Asp (KGD) sequence, whereas tirofiban is a nonpeptide derivative of tyrosine.
